Page last updated: 2024-11-05

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Pulmonary Hypertension

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole has been researched along with Pulmonary Hypertension in 2 studies

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole: antineoplastic; activates platelet guanylate cyclase; a radiosensitizing agent and guanylate cyclase activator; structure in first source
lificiguat : A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Li, L1
Zhang, W1
Lin, F1
Lu, X1
Chen, W1
Li, X1
Zhou, X1
Su, R1
Wang, L1
Zheng, Z1
Li, S1
Huh, JW1
Kim, SY1
Lee, JH1
Lee, YS1

Other Studies

2 other studies available for 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Pulmonary Hypertension

ArticleYear
Synthesis and biological evaluation of pyrazolo[3,4-b]pyridine-3-yl pyrimidine derivatives as sGC stimulators for the treatment of pulmonary hypertension.
    European journal of medicinal chemistry, 2019, Jul-01, Volume: 173

    Topics: Animals; Antihypertensive Agents; Dose-Response Relationship, Drug; Hypertension, Pulmonary; Male; M

2019
YC-1 attenuates hypoxia-induced pulmonary arterial hypertension in mice.
    Pulmonary pharmacology & therapeutics, 2011, Volume: 24, Issue:6

    Topics: Animals; Cell Proliferation; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p21; Endothelin-1; E

2011